Imbrium initiates phase 2 study of IMB-115 in insomnia associated with alcohol cessation

This article was originally published here

IMB-115 is an internally discovered compound with a novel mechanism of action in clinical development for the treatment of insomnia disorders, including insomnia associated with alcohol cessation (IAAC).

The post Imbrium initiates phase 2 study of IMB-115 in insomnia associated with alcohol cessation appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply